FRANKLIN LAKES, N.J., July 25, 2012 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company), today announced the launch of the BD Hyflow™ needle, a unique 27-gauge thin-wall needle designed for use with BD's prefillable syringe systems.
The optimized inner diameter of the BD Hyflow needle enables injection of highly-viscous drug formulations without the use of a larger needle that could be more painful for the patient. As there are an increasing number of highly-viscous formulations in pharmaceutical pipelines today, new needle technologies are essential for patient comfort and device integration.
The BD Hyflow needle increases flow to facilitate use with auto injectors and infusors. This new needle technology also reduces the pressure required to inject, a critical attribute for patients with dexterity limitations. Furthermore, there is evidence to suggest that advanced needle technologies can help patients adhere to their treatment regimens.
"One critical, but often overlooked, factor in selecting a drug delivery system is the needle. As the conduit for drugs to enter the body, and the critical interface with the patient, needles can have a profound effect on the patient experience," said Eric Borin, Vice President and General Manager – Americas, BD Medical – Pharmaceutical Systems. "As a leader in the field of prefillable syringes and needle technology, it is essential that we continuously innovate to meet the needs of our customers. This new needle technology provides biotechnology companies with an alternative to a larger needle gauge."
The BD Hyflow needle has been designed and optimized to exceed ISO standards for thin wall inner diameter needles. BD is the only manufacturer of this unique 27-gauge thin-wall needle for use with a prefillable syringe. Multiple biotechnology companies have commenced stability studies and clinical evaluation with this new technology.
This is one of several new products that BD Medical – Pharmaceutical Systems plans to launch over the next 18 months to enhance the performance of prefilled syringe systems.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD-Becton Dickinson